Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.

Sunil Sharma,E. Gabriela Chiorean,Angela Tatiana Alistar,Fadi S. Braiteh,Marc R. Matrana,Carlos Becerra,Berta Grigorian,Shihe Hou,Anita Schmid,Neil Desai

Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.

2020

Sunil Sharma
E. Gabriela Chiorean
Angela Tatiana Alistar
Fadi S. Braiteh
Marc R. Matrana
Carlos Becerra
Berta Grigorian
Shihe Hou
Anita Schmid
Neil Desai

e16050Background: The PI3K/mTOR pathway overactivation and loss of PTEN occur in 20-40% of mCRC pts. A recent phase 1/2 study in mCRC pts showed evidence that everolimus added to 1L SOC treatment i...

Keywords:

Colorectal cancer
Bevacizumab
Oncology
multi center study
Sirolimus
Internal medicine
in patient
Pathology
first line
Medicine
PTEN

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations